Комбинированное использование препарата кэмпас и тотального облучения кожи при грибовидном микозе
https://doi.org/10.17650/1818-8346-2007-0-1-42-47
Аннотация
В статье приведены обзор литературы и описание клинического случая успешного применения препарата кэмпас в комбинации с тотальным облучением кожи при грибовидном микозе.
Об авторах
В. А. Доронин
ЦКБ №2 им. Н.А. Семашко ОАО РЖД
Россия
Россия
Ю. А. Криволапов
Областное патанатомическое бюро
Россия
Россия
Санкт-Петербург
А. В. Нечеснюк
ЦКБ №2 им. Н.А. Семашко ОАО РЖД
Россия
Россия
А. В. Пивник
РМАПО
Россия
Россия
Кафедра гематологии и интенсивной терапии
Список литературы
1. Willemze R., Jaffe E.S., Burg G. et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768—85.
2. Kim Y.H., Lin H.L., Mrar-Gernhard S. et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003;139(7):857—66.
3. Massone C., Kodama K., Kerl H., Cerroni L. Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol 2005; 29: 550—60.
4. Pimpinelli N., Olsen E.A., Santucci M. et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005;53:1053—63.
5. Nickoloff B.J. Light-microscopic assessment of 100 patients with patch/plaque-stage mycosis fungoides. Am J Dermatopathol 1988;10:469—77.
6. Ralfkiaer E. Controversies and discussion on early diagnosis of cutaneous T-cell lymphoma. Phenotyping Dermatol Clin 1994;12:329—34.
7. Karenko L., Hyytinen E., Sarna S., Ranki A. Chromosomal abnormalities in cutaneous T-cell lymphoma and in its premalignant conditions as detected by G-banding and interphase cytogenetic methods. J Invest Dermatol 1997;108:22—9.
8. Smoller B.R., Santucci M., Wood G.S., Whittaker S.J. Histopathology and genetics of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003;17:1277—311.
9. Bunn P.A., Lamberg S.I. Report of the Committee on Staging and Classification of Cutaneous T-cell Lymphomas. Cancer Treat Rep 1979;63(4):725—8.
10. Gilchrest B.A., Parrish J.A., Tanenbaum L. et al. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976;38:683—98.
11. Roenigk H.H. Photochemotherapy for mycosis fungoides: long-term follow-up study. Cancer Treat Rep 1979;63:669—73.
12. Roupe G., Sandstro m M.H., Kjellstrom C. PUVA in early mycosis fungoides may give long-term remission and delay extracutaneous spread. Acta Dermatol Venereol (Stockh) 1996;76:475—8.
13. Kuzel T.M., Roenigk H.H., Samuelson E. et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol 1995;13:257—63.
14. Rupoli S., Barolli S., Guiducci B. et al. Low dose interferon-a 2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Haematologica 1999;84:809—13.
15. Stadler R., Otte H.-G., Kohl H.P. et al. Prospective randomized multicenter clinical trial on the use of interferon-a 2a plus acitretin versus interferon-a 2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998;92:3578—81.
16. Kaye FJ., Bunn P.A., Steinberg S.M. et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:1784—90.
17. Edelson R., Berger C., Gasparro F. et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med 1987;316:297—303.
18. Evans A.V., Wood B.P., Scarisbrick J.J. et al. Extracorporeal photopheresis in Sezary syndrome: hematologic parameters as predictors of response. Blood 2001;98:1298—301.
19. Micialy B., Miyamoto C., Kantor G. et al. Radiotherapy for unilesional mycosis fungoides. Intern J Radiat Oncol Biol Phys 1998;42:361—4.
20. Rosenblatt E., Kuten A., Leviov M., Cederbaum M. Total skin electron irradiation in mycosis fungoides: dose and fractionation considerations. Leuk Lymphoma 1998;30:143—51.
21. Akpek G., Koh H.K., Bogen S. et al. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999;86:1368—76.
22. Bunn P.A., Hoffman S.J., Norris D. et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994;121:592—602.
23. Kurzrock R., Pilat S., Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 1999;17:3117—21.
24. Kuzel T.M., Hurria A., Samuelsson E. et al. Phase II trial of 2-chlorodeoxyadino-sine for the treatment of cutaneous T-cell lymphoma. Blood 1996;87:906—11.
25. Zackheim H.S., Kashani-Sabet M., Hwang S.T. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996;34:626—31.
26. vanderSpek J.C., Mindell J.A., Finkelstein A., Murphy J.R. Structure/function analysis of the transmembrane domain of DAB389-inter-leukin-2, an interleukin-2 receptor-targeted fusion toxin. The amphipathic helical region of the transmembrane domain is essential for the efficient delivery of the catalytic domain to the cytosol of target cells. J Biol Chem 1993;268:12077—82.
27. Dyer M.J., Hale G., Hayhoe F.G., Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989;73:1431—9.
28. Greenwood J., Clark M., Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 1993;23:1098—104.
29. Heit W., Bunjes D., Wiesneth M. et al. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. Br J Haematol 1986;64:479—86.
30. Reichmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature 1998;332:323—7.
31. Rowan W., Tite J., Topley P., Brett S.J. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998;95:427—36.
32. Ginaldi L., De Martinis M., Matutes E. et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to CAMPATH-1H. Leuk Res 1998;22:185—92.
33. Hale G., Dyer M.J.S., Clark M.R. et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988;2:1394—9.
34. Dearden C.E., Matutes E., Cazin B. et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001;98:1721—6.
35. Lundin J., Hagberg H., Repp R. et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:4267—72.
Рецензия
Для цитирования:
Доронин В.А., Криволапов Ю.А., Нечеснюк А.В., Пивник А.В. Комбинированное использование препарата кэмпас и тотального облучения кожи при грибовидном микозе. Онкогематология. 2007;(1):42-47. https://doi.org/10.17650/1818-8346-2007-0-1-42-47
For citation:
Doronin V.A., Krivolapov Y.A., Nechesnyuk A.V., Pivnik A.V. Combined use of Campath and total skin electron beam irradiation in mycosis fungoides. Oncohematology. 2007;(1):42-47. (In Russ.) https://doi.org/10.17650/1818-8346-2007-0-1-42-47
Просмотров:
145
Послать статью по эл. почте 